Head to Head Comparison: ZIVO Bioscience (NASDAQ:ZIVO) & Inhibikase Therapeutics (NYSE:IKT)

Inhibikase Therapeutics (NYSE:IKT) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Valuation and Earnings

This table compares Inhibikase Therapeutics and ZIVO Bioscience’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	$260,000.00	36.93	-$19.03 million	($3.33)	-0.40
ZIVO Bioscience	$30,000.00	940.67	-$7.78 million	($3.80)	-2.24

ZIVO Bioscience has lower revenue, but higher earnings than Inhibikase Therapeutics. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Inhibikase Therapeutics has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500. Comparatively, ZIVO Bioscience has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500.

Profitability

This table compares Inhibikase Therapeutics and ZIVO Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-147.03%	-116.72%
ZIVO Bioscience	-11,068.75%	N/A	-677.15%

Analyst Recommendations

This is a summary of current recommendations and price targets for Inhibikase Therapeutics and ZIVO Bioscience, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	0	0	1	0	3.00
ZIVO Bioscience	0	1	0	0	2.00

Inhibikase Therapeutics currently has a consensus price target of $23.00, indicating a potential upside of 1,629.32%. Given Inhibikase Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Inhibikase Therapeutics is more favorable than ZIVO Bioscience.

Insider and Institutional Ownership

3.8% of Inhibikase Therapeutics shares are owned by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are owned by institutional investors. 14.7% of Inhibikase Therapeutics shares are owned by company insiders. Comparatively, 21.5% of ZIVO Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Inhibikase Therapeutics beats ZIVO Bioscience on 9 of the 14 factors compared between the two stocks.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

About ZIVO Bioscience

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.